A Feasibility and Safety Study of CD38 CAR-T Cell Immunotherapy for Relapsed B-cell Acute Lymphoblastic Leukemia After CD19 CAR-T Adoptive Cellular Immunotherapy
Clinical trial NCT03754764 · UNKNOWN
Trial details
- NCT number
- NCT03754764
- Sponsor
- Chinese PLA General Hospital
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-11-23
- Primary completion
- 2022-11-23
- Enrollment
- 80
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.